Race Oncology Non-Executive Director Dr. John Cullity speaks with Proactive Investors about the company’s cancer chemotherapy drug, Bisantrene.
L36, 1 Macquarie Place, Sydney
+61 2 8051 3043
Race Oncology is a specialty pharmaceutical company whose business model is to pursue later stage drug assets, principally in the cancer field. Our first important asset is a chemotherapy drug called Bisantrene.
Get the latest news and updates